Status:

COMPLETED

Performance of AclarusDx® a Blood-Based Transcriptomic Test for AD, in French Patients Newly Referred to a Memory Center

Lead Sponsor:

Diaxonhit

Collaborating Sponsors:

Olivier SOL, MD

Conditions:

Cognitive Impairment

Memory Complaint

Eligibility:

All Genders

18+ years

Brief Summary

The purpose of this study is to assess the performance of AclarusDx™, an investigational blood test detecting gene expression information, and intended to help physicians in making an Alzheimer's Dise...

Detailed Description

The objective of this study is to apply AclarusDx™ signature in 600 patients newly referred in french memory centers. Only AclarusDx™ will be added to the panel of tests usually performed at the cente...

Eligibility Criteria

Inclusion

  • male and female adult patients
  • suffering from cognitive impairment and/or memory complaint and justifying a first clinical investigation at the memory center

Exclusion

  • patient already followed up by the memory center
  • patient unable to comply with study procedures

Key Trial Info

Start Date :

December 1 2011

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

December 1 2013

Estimated Enrollment :

606 Patients enrolled

Trial Details

Trial ID

NCT02221661

Start Date

December 1 2011

End Date

December 1 2013

Last Update

August 22 2014

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Performance of AclarusDx® a Blood-Based Transcriptomic Test for AD, in French Patients Newly Referred to a Memory Center | DecenTrialz